Kyverna Therapeutics Inc.

2.16
0.03 (1.41%)
At close: Apr 24, 2025, 3:59 PM
2.10
-2.78%
After-hours: Apr 24, 2025, 06:57 PM EDT

Kyverna Therapeutics Statistics

Share Statistics

Kyverna Therapeutics has 43.22M shares outstanding. The number of shares has increased by 0.23% in one year.

Shares Outstanding 43.22M
Shares Change (YoY) 0.23%
Shares Change (QoQ) 0.1%
Owned by Institutions (%) 66.01%
Shares Floating 19.63M
Failed to Deliver (FTD) Shares 293
FTD / Avg. Volume 0.08%

Short Selling Information

The latest short interest is 2.95M, so 6.82% of the outstanding shares have been sold short.

Short Interest 2.95M
Short % of Shares Out 6.82%
Short % of Float 8.64%
Short Ratio (days to cover) 8.17

Valuation Ratios

The PE ratio is -1.12 and the forward PE ratio is -0.53. Kyverna Therapeutics's PEG ratio is 0.

PE Ratio -1.12
Forward PE -0.53
PS Ratio 0
Forward PS 0.8
PB Ratio 0.54
P/FCF Ratio -1.23
PEG Ratio 0
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Kyverna Therapeutics.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 8.61, with a Debt / Equity ratio of 0.03.

Current Ratio 8.61
Quick Ratio 8.61
Debt / Equity 0.03
Debt / EBITDA -0.06
Debt / FCF -0.07
Interest Coverage 1004.25

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $0
Profits Per Employee $-1.14M
Employee Count 112
Asset Turnover 0
Inventory Turnover n/a

Taxes

Income Tax 0
Effective Tax Rate 0%

Stock Price Statistics

The stock price has increased by -87.86% in the last 52 weeks. The beta is 2.58, so Kyverna Therapeutics's price volatility has been higher than the market average.

Beta 2.58
52-Week Price Change -87.86%
50-Day Moving Average 2.41
200-Day Moving Average 4.89
Relative Strength Index (RSI) 49.05
Average Volume (20 Days) 347.39K

Income Statement

Revenue n/a
Gross Profit 0
Operating Income -142.6M
Net Income -127.48M
EBITDA -142.6M
EBIT -127.62M
Earnings Per Share (EPS) -3.33
Full Income Statement

Balance Sheet

The company has 96.62M in cash and 8.24M in debt, giving a net cash position of 88.38M.

Cash & Cash Equivalents 96.62M
Total Debt 8.24M
Net Cash 88.38M
Retained Earnings -263.52M
Total Assets 304.64M
Working Capital 256.85M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -114.25M and capital expenditures -2.21M, giving a free cash flow of -116.45M.

Operating Cash Flow -114.25M
Capital Expenditures -2.21M
Free Cash Flow -116.45M
FCF Per Share -3.04
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

KYTX does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for KYTX is $20, which is 830.2% higher than the current price. The consensus rating is "Buy".

Price Target $20
Price Target Difference 830.2%
Analyst Consensus Buy
Analyst Count 5
Stock Forecasts

Scores

Altman Z-Score -0.15
Piotroski F-Score 3